Götze, K;Müller-Thomas, C;Peschel, C
The role of azacitidine in the management of myelodysplastic syndromes (MDS).
Cancer Manag. Res.
2009
1
119-30

Schlee, M;Roth, A;Hornung, V;Hagmann, CA;Wimmenauer, V;Barchet, W;Coch, C;Janke, M;Mihailovic, A;Wardle, G;Juranek, S;Kato, H;Kawai, T;Poeck, H;Fitzgerald, KA;Takeuchi, O;Akira, S;Tuschl, T;Latz, E;Ludwig, J;Hartmann, G
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.
Immunity
2009
31
1
25-34

Haas, T;Schmitz, F;Heit, A;Wagner, H
Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells.
Immunology
2009
126
2
290-8

Schlee, M;Roth, A;Hornung, V;Hagmann, CA;Wimmenauer, V;Barchet, W;Coch, C;Janke, M;Mihailovic, A;Wardle, G;Juranek, S;Kato, H;Kawai, T;Poeck, H;Fitzgerald, KA;Takeuchi, O;Akira, S;Tuschl, T;Latz, E;Ludwig, J;Hartmann, G
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.
Immunity
2009
31
1
25-34

Besch, R;Poeck, H;Hohenauer, T;Senft, D;Häcker, G;Berking, C;Hornung, V;Endres, S;Ruzicka, T;Rothenfusser, S;Hartmann, G
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.
J Clin Invest
2009
119
8
2399-411

Bourquin, C;Schmidt, L;Lanz, AL;Storch, B;Wurzenberger, C;Anz, D;Sandholzer, N;Mocikat, R;Berger, M;Poeck, H;Hartmann, G;Hornung, V;Endres, S
Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7.
J Immunol
2009
183
10
6078-86

Ablasser, A;Poeck, H;Anz, D;Berger, M;Schlee, M;Kim, S;Bourquin, C;Goutagny, N;Jiang, Z;Fitzgerald, KA;Rothenfusser, S;Endres, S;Hartmann, G;Hornung, V
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes.
J Immunol
2009
182
11
6824-33

Hochhaus, A;O'Brien, SG;Guilhot, F;Druker, BJ;Branford, S;Foroni, L;Goldman, JM;Müller, MC;Radich, JP;Rudoltz, M;Mone, M;Gathmann, I;Hughes, TP;Larson, RA
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Leukemia
2009
23
6
1054-61

Pirker, R;Pereira, JR;Szczesna, A;von Pawel, J;Krzakowski, M;Ramlau, R;Vynnychenko, I;Park, K;Yu, CT;Ganul, V;Roh, JK;Bajetta, E;O'Byrne, K;de Marinis, F;Eberhardt, W;Goddemeier, T;Emig, M;Gatzemeier, U
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Lancet
2009
373
9674
1525-31

Löwenberg, B;Ossenkoppele, GJ;van Putten, W;Schouten, HC;Graux, C;Ferrant, A;Sonneveld, P;Maertens, J;Jongen-Lavrencic, M;von Lilienfeld-Toal, M;Biemond, BJ;Vellenga, E;Van Marwijk Kooy, M;Verdonck, LF;Beck, J;Döhner, H;Gratwohl, A;Pabst, T;Verhoef, G
High-dose daunorubicin in older patients with acute myeloid leukemia.
N Engl J Med
2009
361
13
1235-48